Esophageal motility disorder

Global Smart Pills Technology Market Report 2023: Sector is Expected to Reach $7,500 Billion by 2030 at a CAGR of 8.8% - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 11, 2023

The global Smart Pills Technology market is a growing segment in the transportation industry.

Key Points: 
  • The global Smart Pills Technology market is a growing segment in the transportation industry.
  • The global smart pills technology market is expected to grow significantly over the forecast period due to increasing demand for non-invasive diagnostic tools and personalized medicine.
  • Additionally, advancements in wireless communication technologies and the miniaturization of electronic components are also driving the growth of the smart pills technology market.
  • Smart Pills Technology Market is segmented based on the Application, target area, disease, end user, and region.

Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board

Retrieved on: 
Tuesday, January 10, 2023

Dr. Lacy has authored over 225 peer reviewed articles

Key Points: 
  • Dr. Lacy has authored over 225 peer reviewed articles
    IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) appointed prominent physician and key opinion leader Brian E. Lacy, M.D., Ph.D., a board-certified gastroenterologist at Mayo Clinic, to its Scientific Advisory Board which is advising the Company on the commercialization of products based on the Biomerica InFoods® Technology platform, beginning with the InFoods® IBS product.
  • I am honored to provide my expertise to Biomerica along with other esteemed members of the Scientific Advisory Board.”
    Dr. Lacy's areas of expertise include irritable bowel syndrome, gastroesophageal reflux disease, dysphagia, achalasia, dyspepsia, gastroparesis, constipation, intestinal pseudo-obstruction and visceral pain.
  • Additionally, Dr. Lacy was the former co-Editor in Chief of the American Journal of Gastroenterology.
  • “Dr.

Hoag Welcomes Dr. Catherine Ngo to Head Digestive Health Institute Motility Program

Retrieved on: 
Monday, November 14, 2022

NEWPORT BEACH, Calif., Nov. 14, 2022 /PRNewswire/ --Hoag has recruited board-certified gastroenterologist Catherine Ngo, M.D., to head the Hoag Digestive Health Institute's Motility Program.

Key Points: 
  • NEWPORT BEACH, Calif., Nov. 14, 2022 /PRNewswire/ --Hoag has recruited board-certified gastroenterologist Catherine Ngo, M.D., to head the Hoag Digestive Health Institute's Motility Program.
  • The Hoag Motility Program is designed to complement the comprehensive care within the Hoag Digestive Health Institute, treating all gastrointestinal disorders from the esophagus to the colon.
  • Dr. Ngo said Hoag's reputation among physicians as a multidisciplinary, collaborative hospital drew her to head the hospital's new program.
  • "Hoag takes a team-based approach to everything it does, which, in the case of digestive disorders, is crucial," Dr. Ngo said.

Solera Health Launches Digestive Health Offering with Best-in-Class Digital Therapy Solutions: Oshi Health and Vivante Health

Retrieved on: 
Monday, March 28, 2022

PHOENIX , March 28, 2022 /PRNewswire/ -- Solera Health, the premier platform for connecting people seamlessly and easily to health solutions that work, announces the launch of its new Digestive Health offering with leading digital therapy solutions: Oshi Health and Vivante Health. These new network partners continue Solera's strategy of bringing programs that address the diverse clinical needs of their payer and employer member populations. All network partners were carefully selected after an extensive vetting process to ensure that they met Solera's high standards for efficacy and customer satisfaction. With Solera's unique value-based payment model, payers and employers get high-quality solutions focused on engagement and industry benchmarked outcomes.

Key Points: 
  • "Digestive Health diseases affect nearly one in five Americans and cost more than $140B per year in direct and indirect costs to employers and health plans," said Mary Langowski, CEO, Solera Health.
  • Oshi Health has redesigned digestive health care around what patients really need and want: convenient, supportive care that quickly achieves sustainable symptom control.
  • Our all-in-one digestive health program, GIThrive, empowers peoplethrough innovative technology, advanced science, and on-demand human supportto improve digestive health, while lowering their cost of care.
  • Vivante Health provides positive patient outcomes at scale for large employers, including multiple fortune 500 companies and leading health plans.

LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia

Retrieved on: 
Wednesday, November 17, 2021

AstraZeneca has been granted Fast Track Designation in the United States (US) for the development of LOKELMA (sodium zirconium cyclosilicate) to reduce arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia (HK).

Key Points: 
  • AstraZeneca has been granted Fast Track Designation in the United States (US) for the development of LOKELMA (sodium zirconium cyclosilicate) to reduce arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia (HK).
  • The designation is based on the potential of LOKELMA to reduce serious adverse CV outcomes in this patient population, addressing a significant unmet medical need.
  • The FDA decision demonstrates the importance of this trial, which will offer important information on LOKELMAs ability to reduce potentially deadly cardiovascular complications associated with hyperkalemia for patients on chronic hemodialysis.
  • DIALIZE-Outcomes is a Phase III randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of LOKELMA on arrhythmia-related cardiovascular outcomes in patients on chronic hemodialysis with recurrent hyperkalemia.

International Foundation for Gastrointestinal Disorders (IFFGD) Presents Virtual Conference for Patients, Families, Friends and Caregivers: The 2021 Nancy and Bill Norton Patient Education Series - IFFGD 30th Anniversary Edition

Retrieved on: 
Wednesday, September 29, 2021

The conference includes talks, lectures, roundtables, and virtual exhibits on the IFFGD website for sponsors and other nonprofit organizations who offer additional patient services and resources.

Key Points: 
  • The conference includes talks, lectures, roundtables, and virtual exhibits on the IFFGD website for sponsors and other nonprofit organizations who offer additional patient services and resources.
  • This year's program is a special edition as 2021 marks the IFFGD nonprofit organization's 30th year anniversary.
  • For a full list of speakers and topics, or to register for the event, please visit the annotated schedule online .
  • "We're extremely pleased to be hosting the Norton Education Series conference again, as it's such a significant resource for so many," said IFFGD President, Ceciel T. Rooker.